Research programme: trastuzumab biosimilar - ISU Abxis

Drug Profile

Research programme: trastuzumab biosimilar - ISU Abxis

Alternative Names: ISU103

Latest Information Update: 12 Mar 2014

Price : $50

At a glance

  • Originator ISU Abxis
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 12 Mar 2014 Preclinical development is ongoing in South Korea
  • 31 Jan 2012 Preclinical trials in Breast cancer in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top